THP-00101

THP-00101 is the dapagliflozin 10 mg component of a fixed-dose combination candidate (dapagliflozin + telmisartan) from THPharm Corp, a small private Korean pharmaceutical sponsor, being evaluated in a Phase 3 trial (NCT06647745) for adults with both type 2 diabetes and essential hypertension [1]. The trial addresses a common comorbidity: hypertension co-occurs in roughly 50% to 70% of adults with type 2 diabetes depending on population and blood-pressure threshold, and combined pharmacologic control of both conditions is current standard of care [4]. The molecular identities of the THP-series components are disclosed in the ClinicalTrials.gov arm descriptions: THP-00101 is dapagliflozin 10 mg (an SGLT2 inhibitor, marketed by AstraZeneca as Farxiga), THP-00102 is telmisartan 80 mg (an angiotensin receptor blocker, originally Micardis, now widely generic), and THP-00103 is telmisartan 40 mg (a lower-dose exploratory arm) [1]. Primary endpoints are change in HbA1c and mean sitting systolic blood pressure at week 12. Estimated primary completion was June 1, 2026 and estimated final completion is December 1, 2026 [1]; as of mid-August 2026, no topline readout has been publicly disclosed. This is a small, single-sponsor program with no US commercial partner announced, no reported Phase 2 publication, and no FDA breakthrough, fast track, or orphan designation. Because both active ingredients are already approved and heavily generic, commercial ceiling is set by fixed-dose combination pricing power and adherence economics, not by novel pharmacology.

THP-00101 is disclosed in the NCT06647745 record as dapagliflozin 10 mg, one arm-labeled component of a dapagliflozin + telmisartan fixed-dose combination program under THPharm's internal code THP-001 [1]. There is no evidence in FDA databases of breakthrough therapy, fast track, orphan drug, or accelerated approval designation, and THPharm has not disclosed a projected US regulatory submission timeline in accessible filings. NCT06647745 is listed as recruiting on ClinicalTrials.gov with a target enrollment of 221 subjects; actual study start was April 10, 2025, estimated primary completion was June 1, 2026, and estimated final completion is December 1, 2026 [1]. As of 2026-08-15, the estimated primary completion date has passed with no public topline results and no update to the trial record indicating an actual completion date. A prior THPharm Phase 1 study, NCT06063109, completed with 51 subjects and evaluated the pharmacokinetic interaction between telmisartan and dapagliflozin [2], which is consistent with the current Phase 3 combination program. Regulatory pathway is presumably through the Korean Ministry of Food and Drug Safety (MFDS) first. A Korea-only Phase 3 registration package would generally not by itself support a US FDA New Drug Application: the FDA typically requires either a US-inclusive multi-regional trial or additional US pivotal data before accepting a foreign-only program, and the 221-subject size and single-site-country design are consistent with an MFDS-only registration intent.

The ClinicalTrials.gov arm descriptions confirm the component identities: THP-00101 is dapagliflozin 10 mg, THP-00102 is telmisartan 80 mg, and THP-00103 is telmisartan 40 mg [1]. Both are approved drugs with well-characterized mechanisms and no ambiguity remains about the pharmacology of the program. SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) block a protein in the kidney called sodium-glucose cotransporter 2 that normally reabsorbs glucose from urine back into blood. When that transporter is blocked, glucose spills into urine, blood sugar drops, and as a side effect fluid volume drops slightly, which lowers blood pressure. SGLT2 inhibitors also produce cardiovascular and kidney-protective effects that go beyond glucose lowering, which is why they are now guideline-recommended in patients with type 2 diabetes plus cardiovascular or renal risk. Angiotensin receptor blockers, or ARBs (telmisartan, losartan, valsartan), block the AT1 receptor that a hormone called angiotensin II uses to constrict blood vessels; blocking that signal relaxes vessels and lowers blood pressure. ARBs also reduce progression of diabetic kidney disease. The mechanistic case for combining these two classes in diabetes-plus-hypertension patients is strong and guideline-supported: both classes independently reduce cardiovascular and kidney events in this population. Because both active ingredients are already approved and used together in clinical practice as separate pills, the incremental clinical benefit of a single-pill fixed-dose combination is largely adherence-driven rather than pharmacology-driven, and the pricing power is correspondingly capped by the availability of the same molecules as cheap generics.

NCT06647745 is a randomized, double-blind, multi-center, active-controlled Phase 3 trial in adults with concurrent type 2 diabetes and essential hypertension, sponsored by THPharm Corp [1]. Listed enrollment target is 221 subjects and status is recruiting. Four arms are disclosed: (1) study group (experimental), dapagliflozin 10 mg + telmisartan 80 mg + placebo; (2) control group 1, dapagliflozin 10 mg monotherapy + telmisartan placebo; (3) control group 2, telmisartan 80 mg monotherapy + dapagliflozin placebo; (4) exploratory group, dapagliflozin 10 mg + telmisartan 40 mg + placebo [1]. All regimens are administered orally daily for 12 weeks. The primary endpoints are change from baseline in mean sitting systolic blood pressure (MSSBP) and hemoglobin A1c (HbA1c) at week 12. HbA1c reflects rolling roughly three-month blood glucose exposure through glycation of hemoglobin, so a twelve-week window is the minimum defensible interval to observe a treatment effect on that endpoint. The two-monotherapy-arm design is the standard fixed-dose combination (FDC, meaning multiple drugs in a single pill) factorial framework used to demonstrate that the combination outperforms each component alone, which is what regulators typically require to approve a branded FDC over the separately available generics. Active-controlled design is appropriate given the ethical problem of withholding treatment from diagnosed hypertension and diabetes. Twelve weeks captures surrogate endpoints (BP and HbA1c) but does not address the cardiovascular and renal outcomes that ultimately drive regulatory value and payer pricing decisions in this population. An enrollment target of 221 across four arms is small for a US-style Phase 3 registrational package but is consistent with an MFDS bioequivalence-plus-superiority package for a fixed-dose combination of two approved generics.

Our model estimates a 16% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 57%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual; it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk. The two-monotherapy-arm factorial design requires the FDC to beat both dapagliflozin monotherapy on the BP endpoint and telmisartan monotherapy on the HbA1c endpoint. That is the standard bar and it is not trivial: telmisartan alone lowers HbA1c very little, so the combination is expected to beat telmisartan on HbA1c largely by virtue of the added SGLT2 inhibitor; the harder test is whether the combination beats dapagliflozin monotherapy on systolic blood pressure by enough to justify the FDC label. A twelve-week primary endpoint captures HbA1c and BP changes but does not touch the cardiovascular and renal outcomes that drive real clinical value in comorbid diabetes-hypertension patients, and payers increasingly demand outcomes data before reimbursing branded FDCs when the same molecules are available as generic pills. Safety risk. Both classes have well-characterized safety profiles. SGLT2 inhibitors carry class risks of euglycemic diabetic ketoacidosis (dangerous acid buildup in the blood even when blood sugar appears normal), genital mycotic infections, and volume depletion; ARBs carry hyperkalemia (dangerously high blood potassium) and acute kidney injury risks, particularly in patients with pre-existing chronic kidney disease. Comorbid diabetes-hypertension patients often have underlying kidney disease, which amplifies both signals, and the combination should be monitored specifically for potassium and volume-status effects. Execution risk. Small sponsor (THPharm Corp is a private Korean venture, headquartered in Cheongju, with roughly $2.87M in disclosed funding as of the K-Bio Bridge profile, focused on incrementally modified and repositioned drugs) [5], a single Phase 3 trial, and no publicly disclosed second confirmatory trial or US IND (Investigational New Drug application, the filing required before starting US clinical trials). A Korea-only registration package would not by itself qualify for FDA approval; a US commercialization path would require additional US pivotal data or a US-inclusive multi-regional trial, neither of which THPharm has announced. Commercial risk. The diabetes-plus-hypertension market is large but crowded, and the specific competitive set for a dapagliflozin + telmisartan FDC includes: AstraZeneca's Xigduo XR (dapagliflozin + metformin extended release), Qternmet XR (dapagliflozin + saxagliptin + metformin), and Farxiga monotherapy; Boehringer Ingelheim / Eli Lilly's Jardiance (empagliflozin), which uniquely carries an FDA cardiovascular mortality label; Johnson & Johnson's Invokamet (canagliflozin + metformin); and on the ARB side, Boehringer's Twynsta (telmisartan + amlodipine) and Micardis HCT (telmisartan + hydrochlorothiazide). Dapagliflozin is losing US composition-of-matter exclusivity in 2025 to 2026 with generic dapagliflozin authorized generics and ANDAs entering the market, and telmisartan has been US-generic since 2014. A branded FDC of two soon-to-be-or-already-generic components must show a meaningful adherence, tolerability, or efficacy edge to command pricing, and US payers have grown aggressive about declining branded FDCs when patients can get the same molecules as separate generic pills.

Watch, do not chase. The core factual gap that drove the earlier low-signal rating (unknown molecular identity of THP-00101) is now resolved: ClinicalTrials.gov arm descriptions confirm THP-00101 is dapagliflozin 10 mg, THP-00102 is telmisartan 80 mg, and THP-00103 is a lower telmisartan dose [1]. That materially raises the mechanistic confidence of the program and pulls the true probability of success meaningfully above the stored 39.7% placeholder. What remains low-signal is the commercial thesis. THPharm Corp is a small private Korean sponsor with roughly $2.87M disclosed funding and no US commercial infrastructure [5], and the program is a fixed-dose combination of two approved (and increasingly generic) drugs, which caps pricing power and requires payer-visible adherence or tolerability differentiation to be commercially meaningful. The trial is a plausible KFDA registration package but not a plausible US Phase 3 pivotal on its own. The most important near-term data point: whether THPharm updates the NCT06647745 record to reflect actual primary completion (estimated June 1, 2026 has passed with no update as of 2026-08-15) and whether they release topline HbA1c and MSSBP results. If the readout is positive and either AstraZeneca (as dapagliflozin's originator) or a Korean partner announces a licensing arrangement, that would move the program from a low-visibility Korean FDC filing into a tracked commercial story. Recheck once the trial record updates or a topline release appears; without one of those events, this program remains a small-sponsor Korean registration project rather than a US-relevant investment thesis.